Sivley Melanie D, Wallace Eric L, Warnock David G, Benjamin William J
Department of Optometry and Vision Science, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Department of Medicine, Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Br J Ophthalmol. 2018 Jan;102(1):54-58. doi: 10.1136/bjophthalmol-2016-310088. Epub 2017 May 12.
Fabry disease (FD) is a treatable multisystem disease caused by a defect in the alpha-galactosidase gene. Ocular signs of FD, including corneal verticillata, are among the earliest diagnostic findings. Conjunctival lymphangiectasia (CL) has not previously been associated with FD.
We examined the eyes of a cohort of 13 adult patients, eight men and five women, with documented classic FD, all treated with enzyme replacement therapy (ERT) at the University of Alabama at Birmingham between February 2014 and April 2015. The average age was 48 years with a range of 35-55 years for men and 21-71 years for women. The mean duration of ERT was 8.4 years (men 8.9 years, women 7.6 years) with a range of 4-14 years. Classical Fabry mutations included Q283X, R227X, W236X and W277X. A high resolution Haag-Streit BQ-900 slit lamp with EyeCap imaging system was used to record conjunctival images.
CL was observed in 11 of the 13 patients (85%) despite long-term ERT. Clinical presentations included single cysts, beaded dilatations and areas of conjunctival oedema. Lesions were located within 6 mm of the corneal limbus. Ten of the 13 subjects (77%) had Fabry-related cataracts and all 13 demonstrated bilateral corneal verticillata. Twelve of the 13 patients had evidence of dry eye, 9 of whom were symptomatic, and 10 had peripheral lymphoedema.
CL represents a common but under-recognised ocular manifestation of FD, which persists despite ERT, and is often accompanied by peripheral lymphoedema and dry eye syndrome.
法布里病(FD)是一种可治疗的多系统疾病,由α-半乳糖苷酶基因缺陷引起。FD的眼部体征,包括角膜涡状浑浊,是最早的诊断发现之一。结膜淋巴管扩张(CL)以前未被认为与FD有关。
我们检查了13例成年患者的眼睛,其中8名男性和5名女性,均确诊为典型FD,于2014年2月至2015年4月在阿拉巴马大学伯明翰分校接受酶替代疗法(ERT)治疗。平均年龄为48岁,男性年龄范围为35 - 55岁,女性为21 - 71岁。ERT的平均疗程为8.4年(男性8.9年,女性7.6年),范围为4 - 14年。典型的法布里突变包括Q283X、R227X、W236X和W277X。使用配备EyeCap成像系统的高分辨率Haag-Streit BQ - 900裂隙灯记录结膜图像。
尽管进行了长期ERT治疗,但13例患者中有11例(85%)出现CL。临床表现包括单个囊肿、串珠样扩张和结膜水肿区域。病变位于角膜缘6毫米范围内。其中10例(77%)患者患有法布里相关白内障,所有13例均有双侧角膜涡状浑浊。13例患者中有12例有干眼证据,其中9例有症状,10例有外周淋巴水肿。
CL是FD常见但未被充分认识的眼部表现,尽管进行了ERT治疗仍会持续存在,且常伴有外周淋巴水肿和干眼综合征。